Economic Data & Stock Action: Your Daily Briefing

Don’t want emails from us anymore? Click here to unsubscribe

Hello Part-time Trader…👋

Premium Stock Alerts is here with your pre-market cheat sheet. In today's issue, we delve into:

  • Fed's Latest Announcements: Understand the Federal Reserve's recent decisions and economic outlook, and how they might influence the markets.

  • Volume Anomalies: Identify stocks witnessing unusual trading volumes, pointing to potential opportunities or risks.

  • Top Pre-Market Movers: Identify early winners poised for a strong market opening.

  • Market Indices & Sector Overview: Get a snapshot of key market indices and sector performances to gauge the day's potential trends.

  • FDA Approvals & Upcoming Decisions: Keep an eye on the latest FDA approvals and crucial upcoming decisions affecting biotech and pharmaceutical stocks.

Now, let's dive into today's edition for a closer look at the insights and analysis that will shape your trading decisions.


The Only Stock You Need To Buy Now

Don't miss out on this stock. As powerful as it is, the move could be soon and fast. Also get a sneak peek at the system generating these huge winners.

Get This Top Stock Ready To Move Now

Happening Today

✓ 10:30 AM ET – EIA Refinery Crude Runs (WoW)

✓ 10:30 AM ET – Crude Oil Imports

✓ 10:30 AM ET – Distillate Fuel Production

✓ 10:30 AM ET – Cushing Crude Oil Inventories

✓ 10:30 AM ET – Crude Oil Inventories


Stock futures show a mixed bag with S&P 500 leading the pack with a dip of 0.21%, while Dow Jones and NASDAQ trade mixed.



⬇️ -0.21% 



⬆️ 0.17%



⬇️ -0.12%


Most sectors are in the red today, with Real Estate leading the decline at -1.53%.




Consumer Discretionary


-0.52% 🔴

Consumer Staples


+0.07% 🟢



-0.87% 🔴



-0.62% 🔴

Health Care


+0.02% 🟢



-0.20% 🔴



-0.74% 🔴

Real Estate


-1.53% 🔴

Information Technology


+0.23% 🟢

Communication Services


-0.12% 🔴



-1.36% 🔴


Get a FREE Stock Analysis: Don't Guess on a Stocks True Value

Get a full report that tells you what a stock is really worth, how safe the stock is, and if the timing is right to buy the stock. Plus a definitive Buy, Sell, Hold recommendation.

Analyze Any Stock Free

Unusual Volume

📈 Jaguar Health Inc (JAGX) jumped 50.08% to $0.18 on a whopping 604.72 million shares traded after announcing that it has signed an exclusive 5-year in-license agreement with United Kingdom-based Venture Life Group PLC for Venture Life's FDA-approved oral mucositis prescription product, Gelclair, for the U.S. market.

📈 Investors went wild, sending WiSA Technologies Inc (WISA) stock soaring 248.57% to $6.10 on a massive volume of 198.91 million shares after the company’s subsidiary WiSA Association announced that it has executed its fourth 5-year WiSA E licensing agreement with a fourth major HDTV/PTV (Projection TV) brand.

📈 Abnormal activity shook Pacific Biosciences of California Inc (PACB), pushing it down -50.62% to $1.40 on a whopping 65.08 million shares traded. The company announced preliminary, unaudited revenue for the quarter ended March 31, 2024.

📈 Peraso Inc (PRSO) stock recently closed 21.26% upper at $1.54 on substantial volume of 61.38 million shares. This unusual activity came after the company announced that Panasonic System Networks R&D Lab. Co., Ltd. (PSNRD) has adopted Peraso's X710 chipset for its new 60GHz WLAN solution.

📈 China SXT Pharmaceuticals Inc (SXTC) increase by 38.46% in a single trading session, with abnormally high trading volume of 34.44 million shares.


MarketBeat Alert: Escape the market madness with 7 stocks to buy and hold

In this market, investors are asking me if we're about to see a massive correction... or worse. The honest answer is nobody knows. But I DO know a way to stop worrying about the market's next move... Own a select group of stocks that can weather whatever the market has in store. These 7 stocks fit the bill Each one had to pass rigorous testing to make the list.

The result is a select group of high-quality blue-chip stocks.

Premarket Movers

INVO Bioscience, Inc. (INVO) experiences a substantial 88.46% surge in pre-market trading following the reports of fourth quarter and full year 2023 financial results.

Spectaire Holdings Inc. (SPEC) sees a significant 41.23% increase, reaching a pre-market price of $1.12 after announcing strategic distribution partnership with a Fortune 1000 Energy Company.

Clene Inc. (CLNN) demonstrates a noteworthy 12.03% surge, with a pre-market price of $0.34. The company presented the Phase 2 VISIONARY-MS long term extension (LTE) study results at the 2024 American Academy of Neurology (AAN) Annual Meeting in Denver.

Pre Market Gainers

Pre Market Change

Pre Market Volume
































A.I. Pioneer Issues Urgent Warning to Americans

According to one early A.I. pioneer:

"You can either use this as an unfair advantage to grow your wealth, or you can let it ravage your retirement savings. There's no middle option."

Click here to learn more while there's still time.

Important FDA 

Recently Announced

Supernus Pharmaceuticals, Inc. (SUPN) Parkinson's drug SPN-830 received a setback on April 8, 2024 with a Complete Response Letter from the FDA, requiring more work before approval.

AbbVie (ABBV) achieved a major win on March 22, 2024 as the FDA granted full approval for their ovarian cancer drug ELAHERE, previously approved on an accelerated basis.

Bristol-Myers Squibb Co. (BMY) celebrated a milestone on March 7, 2024 with the FDA approval of Opdivo for use with chemotherapy in treating urothelial carcinoma, offering a new first-line treatment option for some patients.

Upcoming Announcements

The FDA has a busy April schedule with key decisions on three drugs that could significantly impact treatment options in different areas:

ImmunityBio (IBRX) awaits an April 23rd decision on N-803 for bladder cancer, potentially offering a new approach to managing the disease.

Aquestive Therapeutics Inc. (AQST) hopes for an April 28th approval of Libervant for childhood epilepsy, potentially transforming treatment for this age group.

XOMA Corporation (XOMA) anticipates an April 30th decision on tovorafenib for pediatric glioma, potentially providing new hope for children with this cancer.

🎁 Looking for More? Check out these complementary newsletters for diverse perspectives:

BraVoCycles NewsletterMarket Timing and Price Projections

Happy investing,

Maeve Grace
Editor In Cheif
Premium Trade Alerts

Important: This newsletter does not provide investment advice. The stocks mentioned should not be taken as recommendations. Your investments are solely your decisions.

Disclosure: I hold no positions in any companies mentioned, either through stock ownership, options, or other derivatives. I wrote this article myself, and it expresses my own opinions. I have no business relationship with any company whose stock is mentioned in this article.

Join the conversation

or to participate.